UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2009

AMICUS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware	001-33497	71-0869350
(State or other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

6 Cedar Brook Drive, Cranbury, NJ	08512
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s telephone number, including area code: (609) 662-2000

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 7, 2009, Sol J. Barer, Ph.D., was elected to the Board of Directors of Amicus Therapeutics, Inc. (the “Company”). Dr. Barer will fill the vacancy created by Dr. Gregory M. Weinhoff’s resignation from the Board of Directors which was effective on the same date. Dr. Barer will join the Board of Directors as an independent director and will serve on the Compensation Committee. Current Board of Directors member P. Sherrill Neff will replace Dr. Weinhoff on the Audit Committee.

There is no arrangement or understanding between Dr. Barer and any other person pursuant to which Dr. Barer was elected as director of the Company. There are no relationships or transactions in which Dr. Barer has or will have an interest, or was or is a party, requiring disclosure under Item 404(a) of Regulation S-K.

A copy of the press release announcing Dr. Barer’s election is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d)  Exhibits .

99.1      Press Release, dated January 8, 2009

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AMICUS THERAPEUTICS, INC.
Date: January 8, 2009	By:	/s/ GEOFFREY P. GILMORE
	Name:	Geoffrey P. Gilmore
	Title:	Senior Vice President and General Counsel

3

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release, dated January 8, 2009